I think your position is 'disgusting', in the scenario where kids are in fact dying, safety has not been questioned, there is no alternative treatment, and even you have begrudgingly admitted there is promise. Sector specialists have been much more encouraged, as you know.
There is nothing in this scenario to prevent post-approval trial(s) to continue to re-assess merit.
Ann: Mesoblast Partners with BMT CTN on Adult SR-aGVHD Trial, page-185
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.09 |
Change
0.060(5.85%) |
Mkt cap ! $1.238B | |||
| Open | High | Low | Value | Volume |
| $1.03 | $1.10 | $1.02 | $6.406M | 6.038M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 313712 | $1.08 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.09 | 100000 | 1 |
View Market Depth
| Last trade - 16.10pm 17/05/2024 (20 minute delay) ? |
|
|||||
|
Last
$1.08 |
Change
0.060 ( 5.29 %) |
||||
| Open | High | Low | Volume | ||
| $1.03 | $1.10 | $1.02 | 928883 | ||
| Last updated 15.59pm 17/05/2024 ? | |||||
| MSB (ASX) Chart |